Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

PR Newswire 8 days ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

PR Newswire November 18, 2024

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

PR Newswire November 7, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

PR Newswire October 31, 2024

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

PR Newswire October 10, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

PR Newswire October 8, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

PR Newswire October 2, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

PR Newswire September 30, 2024

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

PR Newswire September 5, 2024

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire August 27, 2024

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

PR Newswire August 8, 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

PR Newswire June 25, 2024

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

PR Newswire June 10, 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

PR Newswire May 9, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

PR Newswire May 8, 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

PR Newswire May 1, 2024

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

PR Newswire April 11, 2024

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

PR Newswire March 28, 2024

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

PR Newswire March 25, 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

PR Newswire March 7, 2024